• Prescribing Information
  • Medical Information
  • Related: See information on our hemophilia B product

    • Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve.

    Click here to learn how we are responding.

    A factor VIII that can help your patients live actively

    Indicated for bleed treatment, control, and protection.​​​​​​​1

    ​​​​​​​XYNTHA SOLOFUSE can help your patients live actively.

    Meet the patients

    Proven Efficacy​​​​​​​1

    XYNTHA is indicated for bleed treatment, control, and protection in adults and children with hemophilia A

    See the data

    ** This is an optional area where footnotes can live.

    Established Safety Profile​​​​​​​1

    Across clinical trials of previously treated patients (PTPs), XYNTHA has demonstrated a low rate of inhibitor formation

    See the data

    ** This is an optional area where footnotes can live.

    All-In-One Reconstitution1

    XYNTHA SOLOFUSE comes in a travel-ready kit and keeps your patients ready to infuse on the go

    See the kit

    ** This is an optional area where footnotes can live.

    Resources

    • Pfizer Factor Savings Card
    • Trial Prescription Program
    See the information

    ** This is an optional area where footnotes can live.

    Reference:

    1. XYNTHA SOLOFUSE. Prescribing information. Pfizer Inc.; 2020.

    • Do not use in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including hamster proteins.
    • Allergic-type hypersensitivity reactions, including anaphylaxis, are possible with XYNTHA. Inform patients of the early signs or symptoms of hypersensitivity reactions (including hives, generalized urticaria, chest tightness, wheezing, and hypotension) and anaphylaxis. Discontinue XYNTHA if hypersensitivity symptoms occur and administer appropriate emergency treatment. XYNTHA contains trace amounts of hamster proteins. Patients may develop hypersensitivity to these proteins.
    • Inhibitors have been reported following administration of XYNTHA. Monitor patients for the development of factor VIII inhibitors by appropriate clinical observations and laboratory tests.
    • Clinical response to XYNTHA may vary. If bleeding is not controlled with the recommended dose of factor, determine the plasma level and administer a dose of XYNTHA sufficient to achieve clinical response. If the factor level does not increase or there is no response, suspect an inhibitor and perform appropriate testing.
    • Across all studies, the most common adverse reactions (≥10%) with XYNTHA in previously treated adult and pediatric patients were headache (24% of subjects), arthralgia (23%), fever (23%), and cough (12%). Other adverse reactions reported in ≥5% of subjects were diarrhea, vomiting, and weakness.
    • XYNTHA is an injectable medicine administered by intravenous (IV) infusion. Patients should be advised that local irritation may occur when infusing XYNTHA after reconstitution in XYNTHA® SOLOFUSE®.

    XYNTHA® Antihemophilic Factor (Recombinant) is indicated in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, for perioperative management, and for routine prophylaxis to reduce the frequency of bleeding episodes. 

    XYNTHA is not indicated in patients with von Willebrand’s disease. 

    Please see full Prescribing Information for XYNTHA and XYNTHA SOLOFUSE.

    Indication

    XYNTHA® Antihemophilic Factor (Recombinant) is indicated in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, for perioperative management, and for routine prophylaxis to reduce the frequency of bleeding episodes. 

    XYNTHA is not indicated in patients with von Willebrand’s disease. 

    Please see full Prescribing Information for XYNTHA and XYNTHA SOLOFUSE.